Day: December 5, 2018

Kezar Life Sciences to Present at The BMO Prescriptions for Success Healthcare Conference

From Startup Kezar Life Sciences Link to Full Article: http://investors.kezarlifesciences.com/news-releases/news-release-details/kezar-life-sciences-present-bmo-prescriptions-success-healthcare SOUTH SAN FRANCISCO, Calif., Dec. 05, 2018 (GLOBE NEWSWIRE) — Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that John Fowler, Chief

Aptinyx to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

From Startup Aptinyx Link to Full Article: https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-present-bmo-capital-markets-2018-prescriptions-success EVANSTON, Ill., Dec. 05, 2018 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will participate in a fireside chat

Anika Resumes Global Distribution of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX

From Startup Anika Therapeutics Link to Full Article: http://ir.anikatherapeutics.com/news-releases/news-release-details/anika-resumes-global-distribution-hyalofast-hyalograft-c-and Company Expands HYALOFAST Commercial Reach in Asia, the Middle East and Latin America BEDFORD, Mass.–(BUSINESS WIRE)–Dec. 4, 2018– Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”)

Kallyope Inc. Announces $21 Million Expansion of Series B Financing

From Startup Kallyope Link to Full Article: https://www.kallyope.com/kallyope-inc-announces-21-million-expansion-series-b-financing/ December 5th, 2018 Entry of Bill Gates and additional investment from existing syndicate raises Series B total to $87 million Kallyope Inc., a leading biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, today announced a $21 million expansion of

BrainStorm Cell Therapeutics to Present at the 29th International Symposium on ALS/MND

From Startup Brainstorm Cell Therapeutics Link to Full Article: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2379449 Poster highlights enrichment strategies for clinical trials in ALS NEW YORK, Dec. 04, 2018 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today that